Semaglutide injections, which have become a popular treatment option for weight loss as well as Type 2 diabetes, have been considered to be in a shortage since 2022. This could affect Hims & Hers, ...
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.
The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration ...
In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
Researchers said the study backs up anecdotal evidence from patients and doctors that semaglutide can lead to a sudden loss ...
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
(Reuters) - A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has ...
A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...
American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic anterior optic neuropathy (NAION).